Related Experiment Video

Updated: Mar 28, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Matrix Metalloproteinase 3 Gene Polymorphism and Its Level Predict Morbidity After Acute Myocardial Infarction

Tarek A Abd El-Aziz1, Randa H Mohamed2

  • 1From the Cardiology Department.

American Journal of Clinical Pathology
|December 30, 2015
PubMed
Abstract

Insights

Matrix metalloproteinase 3 (MMP-3) gene variants and elevated MMP-3 levels predict complications after acute myocardial infarction (AMI). The 5A/5A genotype is linked to increased morbidity and impaired left ventricular function post-MI.

Area of Science:

  • Cardiology
  • Genetics
  • Biochemistry

Background:

  • Matrix metalloproteinases (MMPs) play a crucial role in ventricular remodeling following acute myocardial infarction (MI).
  • Matrix metalloproteinase 3 (MMP-3) is implicated in post-MI cardiac remodeling.
  • Genetic variations in MMP genes may influence patient outcomes after MI.

Purpose of the Study:

  • To investigate the association between MMP-3 gene polymorphism (5A/6A) and serum MMP-3 levels with morbidity after acute myocardial infarction (AMI).
  • To determine if MMP-3 status predicts adverse outcomes and left ventricular dysfunction in AMI patients.

Main Methods:

  • A cohort of 112 patients with AMI and 140 controls were studied.
  • Serum MMP-3 levels were measured, and MMP-3-1612 5A/6A polymorphism was genotyped using polymerase chain reaction.
  • Patients were followed for AMI complications during hospitalization and for 6 months post-discharge.

Main Results:

  • Serum MMP-3 levels were significantly higher in AMI patients who experienced morbidity compared to those without complications.
  • Patients with the MMP-3 5A/5A genotype exhibited elevated MMP-3 levels and a fivefold increased risk of morbidity.
  • The 5A/5A genotype was associated with greater impairment in left ventricular fractional shortening and ejection fraction, and higher MMP-3 levels correlated inversely with these parameters at 6 months.

Conclusions:

  • MMP-3 gene polymorphism, specifically the 5A/5A genotype, is significantly associated with an increased risk of morbidity after AMI.
  • Elevated predischarge serum MMP-3 levels are linked to the development of left ventricular dysfunction in the aftermath of an acute myocardial infarction.
Keywords:
MMP-3MorbidityPolymorphismsPredictors

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
687
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
568
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
417
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68